Dreamtech's Increased Shareholding in Plasmap

Recent news indicates that Dreamtech, the major shareholder of Plasmap, has increased its stock ownership to 51.30%. According to disclosures as of July 30, 2026, Dreamtech and its special related parties hold a total of 1,969,046 shares. This represents an increase of 63,000 shares compared to the previous reporting date of June 19, 2026. The ownership ratio has risen by 1.64 percentage points.

Shareholding Breakdown

Dreamtech holds 1,062,499 shares, accounting for 27.68% of the total. Additionally, its special related party, Namuga, holds 382,315 shares, representing 9.96%. Other special related parties, LimAlexandra and LimCharlesChangwan, possess 238,737 shares and 141,983 shares, respectively, with ownership ratios of 6.22% and 3.70%. Lastly, Lee Yoon-cheol holds 57,022 shares, making up 1.49% of the total.

Changes Driven by Open Market Purchases

The primary reason for this shift in shareholding ratio has been identified as open market purchases. On July 23, 2026, Namuga acquired voting shares on the open market at 5,370 KRW per share, increasing its shareholding from 319,315 shares to 382,315 shares. This strategic move has had a positive impact on Plasmap's stock price.

Plasmap's Financial Status

Plasmap has released its consolidated financial statements for the fiscal year ending December 2025. The company reported total assets of 20.6 billion KRW, total liabilities of 14.8 billion KRW, and total equity of 5.7 billion KRW. Revenue stood at 8.5 billion KRW, with an operating loss of 7.6 billion KRW and a net loss of 6.6 billion KRW. These financial indicators offer insights into the company's growth potential.

Plasmap's Market Position

Plasmap is a specialized deep tech company in bio-plasma, listed on the KOSDAQ market on October 21, 2022. It primarily operates in the manufacturing of medical devices. As of July 30, 2026, its stock price was 4,610 KRW, marking a 290 KRW increase from the previous day, a gain of 6.71%.

These developments are expected to positively influence Plasmap's future, making its upcoming trajectory a subject of keen interest. It is crucial to continuously monitor stock market volatility and the company's financial health.